News

February 1, 2018

AveXis Releases Community Statement on STR1VE

AveXis Releases Community Statement on STR1VE

AveXis has provided the following community statement on AVXS-101.

Dear SMA Community,

AveXis, the gene therapy company developing a new approach to treat SMA known as AVXS‐101, is pleased to initiate screening for the remaining patients to be enrolled in the pivotal trial of...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

January 30, 2018

Preliminary Data from FIREFISH Trial in Type 1 SMA Infants Presented at the International Scientific Congress on Spinal Muscular Atrophy

PTC Therapeutics, Inc. recently announced the presentation of early interim data from Part 1, the dose-finding portion of the FIREFISH study. FIREFISH is a two-part seamless, open-label, multi-center study to investigate the safety and efficacy of RG7916 in infants and babies with Type 1 SMA. RG7916 has been safe and well tolerated at all...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

January 26, 2018

AveXis Releases Community Statement on Expanded Clinical Trials

AveXis Releases Community Statement on Expanded Clinical Trials

AveXis has provided the following community statement on AVXS-101. 

Dear SMA Community, 

At AveXis, the gene replacement therapy company developing a new approach to treat SMA known as AVXS-101, we recently announced our plans to start three new clinical...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

Items 10 - 12 of 435  Previous12345678910Next

© 2018 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software